Search | Clinical Trials Finder

Conditions: Hemophilia A
Interventions: Emicizumab, FEIBA, rFVIIa; Drug
Lead sponsor: Emory University; Other
Eligibility: 6 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hemophilia A
Interventions: rAHF-PFM; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Von Willebrand Diseases
Interventions: Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more

Conditions: Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions: Damoctocog alfa pegol (Jivi, BAY94-9027); Biological
Lead sponsor: Bayer; Industry
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hemophilia A, Congenital
Interventions: Alphanate; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more

Conditions: Acquired Hemophilia A
Interventions: OBI-1; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Bethesda, Maryland + 4 more

Conditions: Hemophilia A
Interventions: rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 70 Years · Male only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Orange, California • Sacramento, California • San Francisco, California + 17 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Recombinant Factor VIIa BI (rFVIIa BI); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Blood Coagulation Disorders, Hemophilia A
Interventions: Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Orange, California • Sacramento, California • Tampa, Florida + 4 more

Conditions: Hemophilia A
Interventions: Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more

Conditions: Haemophilia A
Interventions: Recombinant Factor VIII (Kovaltry, BAY81-8973); Biological
Lead sponsor: Bayer; Industry
Eligibility: 0 Years to 12 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 4
States / cities: New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more

Conditions: Hemophilia A
Interventions: Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Von Willebrand Disease (VWD)
Interventions: rVWF, rFVIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Sacramento, California • St Louis, Missouri • Columbus, Ohio

Conditions: Hemophilia A, Hemophilia B
Interventions: ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant]); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Sickle Cell Disease, Hemolytic Anemia
Interventions: Clinical Evaluations, Laboratory Studies; Procedure · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemophilia A, Hemophilia B
Interventions: marstacimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Liver Transplant Surgery
Interventions: Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF); Biological
Lead sponsor: Trauma Hemostatis and Oxygenation Research (THOR) Network; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hemophilia A
Interventions: Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Peoria, Illinois • Portland, Oregon

Conditions: Hemophilia A
Interventions: Desmopressin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hemophilia A
Interventions: ReFacto, Advante; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Iowa City, Iowa + 1 more

Search by objective public record fields.

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

ADVATE Post Authorization Safety Surveillance

Von Willebrand Factor in Pregnancy (VIP) Study

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Alphanate in Immune Tolerance Induction Therapy

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

BAY81-8973 Pediatric Safety and Efficacy Trial

Emicizumab PUPs and Nuwiq ITI Study

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Long Term Effects of Erythrocyte Lysis

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Fibrinogen in Liver Transplant

GAS-Hem Feasibility Study

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A